资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

MiR-140-3p is Involved in In-Stent Restenosis by Targeting C-Myb and BCL-2 in Peripheral Artery Disease.

J. Atheroscler. Thromb.. 2018;

ZhuZheng-Rong，HeQiong，WuWei-Bin，ChangGuang-Qi，YaoChen，ZhaoYang，WangMian，WangShen-

Products/Services Used	Details	Operation
Catalog Antibody	… The mem- branes were blocked with 5% BSA for 1 h, followed by incubation with primary antibodies overnight at 4℃. The membranes were incubated with HRP-con- jugated secondary antibody (A00098, GenScript, USA). The …	Get A Quote

摘要

In-Stent Restenosis (ISR) is the major reason for recurrent ischemia and amputation after endovascular treatment of Peripheral Artery Disease (PAD). Our previous study demonstrated that miR-140-3p is significantly down-regulated in PAD arteries. However， expression and function of miR-140-3p in ISR of human PAD are currently unclear.The aim of this study is to determine the miR-140-3p expression and its regulative role in ISR of PAD.